Quantinno Capital Management LP Buys 39,195 Shares of ClearPoint Neuro, Inc. $CLPT

Quantinno Capital Management LP increased its stake in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT) by 307.4% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 51,947 shares of the company’s stock after purchasing an additional 39,195 shares during the period. Quantinno Capital Management LP’s holdings in ClearPoint Neuro were worth $473,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in CLPT. Millennium Management LLC grew its position in ClearPoint Neuro by 156.3% in the 1st quarter. Millennium Management LLC now owns 741,193 shares of the company’s stock worth $8,813,000 after purchasing an additional 452,043 shares during the period. SG Americas Securities LLC bought a new position in shares of ClearPoint Neuro during the 1st quarter valued at $3,388,000. FirstWave Capital Management LLC bought a new position in shares of ClearPoint Neuro during the 4th quarter valued at $4,971,000. Two Sigma Investments LP boosted its stake in shares of ClearPoint Neuro by 1,316.1% in the 3rd quarter. Two Sigma Investments LP now owns 310,526 shares of the company’s stock worth $6,766,000 after buying an additional 288,598 shares during the last quarter. Finally, Balyasny Asset Management L.P. purchased a new position in shares of ClearPoint Neuro in the 4th quarter worth $2,972,000. Institutional investors own 30.08% of the company’s stock.

Insider Activity

In other news, Director Timothy T. Richards sold 5,415 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $12.17, for a total value of $65,900.55. Following the transaction, the director owned 87,198 shares of the company’s stock, valued at $1,061,199.66. This trade represents a 5.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Joseph Burnett sold 20,000 shares of ClearPoint Neuro stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $19.38, for a total value of $387,600.00. Following the transaction, the chief executive officer directly owned 116,842 shares in the company, valued at approximately $2,264,397.96. The trade was a 14.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 87,258 shares of company stock valued at $1,553,964 in the last three months. 6.94% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts recently commented on CLPT shares. Stifel Nicolaus set a $22.00 price objective on ClearPoint Neuro in a report on Tuesday, August 4th. Lake Street Capital set a $25.00 target price on ClearPoint Neuro in a research report on Tuesday, August 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of ClearPoint Neuro in a research report on Friday, July 17th. Wall Street Zen downgraded ClearPoint Neuro from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Finally, B. Riley Financial upped their price target on shares of ClearPoint Neuro from $20.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $25.67.

ClearPoint Neuro Trading Up 1.3%

Shares of CLPT stock opened at $15.39 on Friday. ClearPoint Neuro, Inc. has a 1 year low of $8.27 and a 1 year high of $30.10. The firm has a fifty day moving average price of $15.95 and a 200-day moving average price of $13.11. The company has a debt-to-equity ratio of 4.66, a current ratio of 4.74 and a quick ratio of 3.89. The company has a market cap of $469.39 million, a price-to-earnings ratio of -13.04 and a beta of 1.24.

ClearPoint Neuro (NASDAQ:CLPT) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.09). ClearPoint Neuro had a negative return on equity of 188.09% and a negative net margin of 81.76%.The company had revenue of $10.88 million during the quarter, compared to analysts’ expectations of $12.73 million. During the same quarter last year, the company earned ($0.21) earnings per share. As a group, equities analysts predict that ClearPoint Neuro, Inc. will post -1.29 earnings per share for the current year.

ClearPoint Neuro Profile

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.